The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Effect of fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on relapse-free survival in patients with newly diagnosed core-binding factor acute myelogenous leukemia.
Gautam Borthakur
No relevant relationships to disclose
Jorge E. Cortes
No relevant relationships to disclose
Susan Mary O'Brien
No relevant relationships to disclose
Tapan M. Kadia
No relevant relationships to disclose
Zeev Estrov
No relevant relationships to disclose
Stefan Faderl
No relevant relationships to disclose
Farhad Ravandi
No relevant relationships to disclose
Varsha Gandhi
No relevant relationships to disclose
William Plunkett
No relevant relationships to disclose
Joyce Bass
No relevant relationships to disclose
Mark Brandt
No relevant relationships to disclose
Hagop Kantarjian
No relevant relationships to disclose